André Ostachkov
Directeur/Bestuurslid bij DoseVue NV
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Pierre P. de Kettenis de Hollaeken | M | - |
Home EOS NV
Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | 8 jaar |
Aurelien Valet | M | 49 |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | 19 jaar |
Alain Valet | M | 78 |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | 19 jaar |
Staf van Reet | M | - |
DoseVue NV
DoseVue NV Medical SpecialtiesHealth Technology DoseVue NV is developing innovative technologies for convenient and accurate in-vivo dosimetry. It offers DoseWire Series 100 & DoseWire Series 200. The company was founded by Emiliano D Agostino in March 2013 and is headquartered in Turnhout, Belgium. | - |
Jean-Marc Ferrier | M | - |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | 19 jaar |
Jean-Michel Bouler | M | - |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | 19 jaar |
Lotfi Yelles Chaouche | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 5 jaar |
Olivier Greiner | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Michiel Allaerts | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Aude Thibaut de Maisières | F | 49 |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 8 jaar |
Luc Reginster | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Matthieu de Posch | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 6 jaar |
Carsten Engel | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 6 jaar |
Jef Wittouck | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 6 jaar |
Helena Pozios | F | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 5 jaar |
Nicolas Papillon | M | 44 |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | - |
Bernard Clerbois | M | - |
Home EOS NV
Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | 3 jaar |
Colin Loyens | M | - |
Home EOS NV
Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | 3 jaar |
Antoine P. de Kettenis de Hollaeken | M | - |
Home EOS NV
Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | 3 jaar |
Carl Edward van Camp | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Graham Dixon | M | 63 |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 2 jaar |
Pol-Henry Bonte | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 9 jaar |
Benoit Fellin | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 6 jaar |
Christian Fernand Jourquin | M | 76 |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Philippe Dubrou | M | 72 |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | - |
Enrico Jose Adolfo Bastianelli | M | - |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | - |
Thierry Piret | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Johan Keppens | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 6 jaar |
Paul van Dun | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
François Cornélis | M | 74 |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | 9 jaar |
Philippe Tielemans | M | - |
Home EOS NV
Home EOS NV Engineering & ConstructionIndustrial Services Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016. | 3 jaar |
Yves Meurice | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Bruno Paglia | M | - |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | - |
Alain Tornier | M | 78 |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | - |
Frederic Convent | M | - |
Graftys SA
Graftys SA Medical SpecialtiesHealth Technology Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France. | 5 jaar |
Bart Wuurman | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 4 jaar |
Serge Demoulin | M | - |
Innovation Fund (BE)
Innovation Fund (BE) Investment ManagersFinance Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Vicente Vento Bosch | M | 43 |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Alberto Tió | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Montse Suarez | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 4 jaar |
Juan Trían Riu | M | 40 |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Helena Torrás de la Serna | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Gael Jalce | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 2 jaar |
Mario Bonet | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Roger Rafols Solé | M | 50 |
Escuela Superior de Administración y Dirección de Empresas
| 6 jaar |
Milós Esteva Tuñí | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Griselda Garde Monferrer | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Hector Jeronimo Dominguis Perez | M | 48 |
Escuela Superior de Administración y Dirección de Empresas
| 2 jaar |
David Moreno | M | 50 |
Escuela Superior de Administración y Dirección de Empresas
| 3 jaar |
Ferrán Alcácer Vilarmau | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Manuel Cebrián Vélez | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
David Arroyo Sierra | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 2 jaar |
Joan Josep Puig Castro | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 3 jaar |
Albert Ferrer Olivera | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Ana Covaliu | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 2 jaar |
Yulia Germanovna Chupina | F | 53 |
Escuela Superior de Administración y Dirección de Empresas
| - |
Ferrán Sala | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 2 jaar |
María Entrecanales Franco | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 1 jaar |
Carlo Zola | M | 46 |
Escuela Superior de Administración y Dirección de Empresas
| 1 jaar |
Alberto Carrasco | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Pedro Miguel Matos Borges de Oliveira | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 2 jaar |
José-Manuel Villanueva Villalba | M | 48 |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Gustavo Barroeta Torres | M | - |
Escuela Superior de Administración y Dirección de Empresas
| 3 jaar |
Rosa Maria Sanchez Jimenez | F | - |
Escuela Superior de Administración y Dirección de Empresas
| 5 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
België | 28 | 43.75% |
Spanje | 26 | 40.63% |
Frankrijk | 10 | 15.63% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- André Ostachkov
- Persoonlijk netwerk